Co-delivery of docetaxel and curcumin prodrug via dual-targeted nanoparticles with synergistic antitumor activity against prostate cancer
Jieke Yan, Yuzhen Wang, Yuxiu Jia, Shuangde Liu, Chuan Tian, Wengu Pan, Xiaoli Liu, Hongwei Wang
Abstract
Purpose: Combination therapy is increasingly used as a primary cancer treatment regimen. In this report, we designed EGFR peptide decorated nanoparticles (NPs) to co-deliver docetaxel (DTX) and pH sensitive curcumin (CUR) prodrug for the treatment of prostate cancer.
Results: EGFR peptide (GE11) targeted, pH sensitive, DTX and CUR prodrug NPs (GE11-DTX-CUR NPs) had an average diameter of 167nm and a zeta potential of -37.5mV. The particle size of the NPs was adequately maintained in serum and a sustained drug release pattern was observed. Improved inhibition of cancer cell and tumor tissue growth was shown in the GE11-DTX-CUR NPs group compared to the other groups.
Conclusion: It can be summarized that DTX and CUR prodrug could be delivered into tumor cells simultaneously by the GE 11 targeting and the EPR effect of NPs. The resulting GE11-DTX-CUR NPs is a promising system for the synergistic antitumor treatment of prostate cancer.
Schlüsselwörter: Doppelt gezielte Nanopartikel; EGFR-vermittelte Endozytose; Prostatakrebs; Synergistische Kombinationstherapie; Gezieltes Liefersystem.
Verwandte Produkte
Abkürzung: mPEG-NH2
Name: Methoxypoly(ethylenglykol)amin
Für weitere Produktinformationen kontaktieren Sie uns bitte unter:
US-Tel.: 1-844-782-5734
US-Tel.: 1-844-QUAL-PEG
CHN Tel.: 400-918-9898
E-Mail: sales@sinopeg.com
